A promising target for new RNA therapeutics now accessible
Researchers have identified the first inhibitors of the cancer-related RNA-modifier METTL16, which prevent its interaction with RNA. This breakthrough lays the foundation for novel RNA-targeting therapeutics and better investigation of METTL16's role in disease and health.